

From: HOME NOTIFICATIONS D5
Sent: mercredi 16 novembre 2022 16:27
To: HOME NOTIFICATIONS D5
Subject: Open Letter to the European Commission - Enabling reform efforts in the Member States in the sense of effective drug policy
Attachments: Nov2022_OpenLetter_EuropeanCommission_DrugPolicy.pdf; FW: Open Letter to the European Commission - Enabling reform efforts in the Member States in the sense of effective drug policy

From: Cansativa GmbH - Public Affairs <publicaffairs@cansativa.de>
Sent: Wednesday, November 16, 2022 8:00 AM
To: PARIAT Monique (HOME) <Monique.Pariat@ec.europa.eu>
Subject: Open Letter to the European Commission - Enabling reform efforts in the Member States in the sense of effective drug policy

Dear Mrs. Pariat,

In the name of over 20 representatives from the industry and associations in the cannabis industry I am sending you this open letter (please see attachment) and invitation for dialogue.

We, representatives of the European cannabis industry and associations, take note of the fact that progressive approaches towards the use of adult-use cannabis have been prevailing in international comparison for several years. In the European Union, more and more Member States - including Malta, Luxembourg, the Czech Republic and the Netherlands - are embarking to reform their formerly prohibitive drug policies in a result-oriented manner allowing for a new cannabis policy framework covering all its use cases.

For a long time, attempts were made to restrict the cultivation, distribution and consumption of cannabis through prohibitive and repressive drug policies. As a result, the use, availability and THC potency of cannabis in the unregulated illicit market has been increasing, while contamination continues to pose an unpredictable health threat to citizens in the EU^[1]. Finally, the failed drug policies of the past decades have led to organised crime generating billions in revenue year after year.

Most recently, the government of the Federal Republic of Germany has presented a key issues paper on how it intends to transfer the formerly illegal market for adult-use cannabis into a regulated framework. These reforms are in no way contradictory to the global goals of improved health protection. Therefore, **we would welcome a timely, in-depth evaluation of the capacities of European drug policy** under the global drug control treaties by the European Commission. By sharing the German interpretation of those treaties, **the Commission will allow Member States to implement forward-looking drug policies to reach the intentions of our global drug control treaties far more effectively than the previous attempts of blanket prohibition.**

In this comprehensive effort towards a new consensus, the Commission can rely on the support of all stakeholders. We, the diverse European cannabis industry and associations, continuously

^[1]European Monitoring Centre for Drugs and Drug Addiction (2022), *European Drug Report 2022: Trends and Developments*, Publications Office of the European Union, Luxembourg.

work towards increased research and knowledge sharing in the epistemic community. We see ourselves as a resource for evidence-based policy making and are an ideal partner for consultation and subject-matter evaluation. We trust that the EU-Commission will support all endeavours to strengthen a paradigm shift in drug policy.

We assure you of our commitment to engage in constructive dialogue and contribute positively to the critical debate.

Yours faithfully,

Tom Broockmann (Managing Director), ADREXpharma GmbH, Germany

Tej Virk (Director & CEO), Akanda Corp., United Kingdom

Lars Erik Råen (CEO), Balancial AS, Denmark

Dr. rer. medic. David Surjo (CCDO), Canify AG, Germany

Tim Henley (UK Commercial Manager), Cannim Group Pty Ltd, Australia

Stefan Jacker (COO), CanPharma GmbH, Germany

Ioana Freise (Head of Reg. & Public Affairs), Cansativa GmbH, Germany

Matthias Fischer (Managing Director), Canymed GmbH, Germany

Jan Simon (CEO), CZ Pharma s.r.o, Czech Republic

Dr. Constantin von der Groeben (Managing Director), DEMECAN GmbH, Germany

Thomas Schatton (CEO), Four 20 Pharma GmbH, Germany

Oliver Schultz (CCO), Grünhorn, Germany

Šárka Betke (Managing Director) High Five Group s.r.o., Czech Republic

Richard Balla (CEO), IMC adjupharm GmbH, Germany

Jonathan Lubosch-Haenisch (CEO), iuvo Therapeutics GmbH, Germany

Georg Wurth (CEO), German Cannabis Association, Germany

Dr. med. Jaschar Kermany (CEO), Kineo Medical GmbH, Germany

Michal Drdák (Business Director), Lagom Pharmatech s.r.o., Czech Republic

Nick Pateras (Managing Director), Materia Global, United Kingdom

Antonia Menzel (Director Public Affairs & Corp.Spokesperson) Sanity Group GmbH, Germany

Luc Richner (Co-Founder and CEO), Vigia AG, Switzerland

Börge Diessel (Managing Director), WEECO Pharma GmbH, Germany

Ioana Freise

Head of Regulatory & Public Affairs
T: +49 175 3866 201

ioana.freise@cansativa.de

Eingetragene Interessensvertreterin

Cansativa GmbH

Hessenring 15i
64546 Mörfelden-Walldorf
T: +496105 96380 77

www.cansativa-group.com

Registergericht: AG Frankfurt am Main, HRB 108385
Geschäftsführer: Jakob Sons, Benedikt Sons

Die Cansativa GmbH ist mit der Nummer R002380 im Lobbyregister für die Interessenvertretung gegenüber dem Deutschen Bundestag und der Bundesregierung eingetragen und übt Interessenvertretung ausschließlich auf Grundlage des staatlichen Verhaltenskodexes aus.
